Patients with metastatic colorectal cancer that had stopped responding to at least two prior treatment regimens gained ...

Researchers found that an existing FDA-approved drug could make immunotherapy more effective against a rare form of liver ...

In clinical trials, the drug was shown to almost double the survival time for pancreatic cancer patients. Here's how it works and who can get it.

Daraxonrasib was shown to have “landscape-changing” results in extending life expectancy, according to the American Society ...

Adam Friedman, CEO of the Scorpion Therapeutics spinout, said the deal helps both companies accelerate research "faster than ...

A new medication could double survival time in patients with advanced pancreatic cancer, according to Phase III clinical ...

The experimental drug daraxonrasib, which doubled survival time in patients with advanced pancreatic cancer, may also prove effective for lung, colon and ovarian cancers.

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Former Senator Ben Sasse has become an unlikely public face of a drug that researchers are ...

AstraZeneca and Gilead have won approval for treatments of an advanced form of the disease.

The drug is not a cure. Cancers often develop resistance to targeted drugs such as daraxonrasib. Instead, its promise for ...

Most recurrences of the deadliest form of skin cancer develop within the first 2-3 years after treatment, but melanoma can recur even over a decade later, according to the AIM at Melanoma Foundation.

Cancer cells are remarkably good at adapting to stress. When treatments damage them, they often find new ways to survive, ...